Quest Diagnostics Inc. diskutieren
Quest Diagnostics Inc.
WKN: 904533 / Symbol: DGX / Name: Quest Diagnostcs / Aktie / Anbieter & Dienstleistungen / Large Cap /
152,95 €
-0,55 %
Quest Diagnostics Incorporated (NYSE: DGX) had its "buy" rating re-affirmed by analysts at Mizuho. They now have a $165.00 price target on the stock.
Ratings data for DGX provided by MarketBeat
Quest Diagnostics Incorporated (NYSE: DGX) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Ratings data for DGX provided by MarketBeat
Quest Diagnostics Incorporated (NYSE: DGX) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Ratings data for DGX provided by MarketBeat
Quest Diagnostics Incorporated (NYSE: DGX) was upgraded by analysts at Jefferies Financial Group Inc. from a "hold" rating to a "buy" rating. They now have a $155.00 price target on the stock, up previously from $140.00.
Ratings data for DGX provided by MarketBeat
Quest Diagnostics Incorporated (NYSE: DGX) had its price target raised by analysts at Mizuho from $150.00 to $155.00. They now have a "buy" rating on the stock.
Ratings data for DGX provided by MarketBeat
Quest Diagnostics Incorporated (NYSE: DGX) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Ratings data for DGX provided by MarketBeat
Quest Diagnostics Incorporated (NYSE: DGX) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Ratings data for DGX provided by MarketBeat
Quest Diagnostics Incorporated (NYSE: DGX) was upgraded by analysts at Citigroup Inc. from a "neutral" rating to a "buy" rating. They now have a $165.00 price target on the stock, up previously from $145.00.
Ratings data for DGX provided by MarketBeat
Quest Diagnostics Incorporated (NYSE: DGX) had its price target raised by analysts at Citigroup Inc. from $165.00 to $185.00. They now have a "buy" rating on the stock.
Ratings data for DGX provided by MarketBeat
Quest Diagnostics Incorporated (NYSE: DGX) had its price target raised by analysts at Mizuho from $160.00 to $174.00. They now have an "outperform" rating on the stock.
Ratings data for DGX provided by MarketBeat
Quest Diagnostics Incorporated (NYSE: DGX) had its "buy" rating re-affirmed by analysts at Jefferies Financial Group Inc.. They now have a $185.00 price target on the stock.
Ratings data for DGX provided by MarketBeat
Quest Diagnostics Incorporated (NYSE: DGX) had its price target raised by analysts at Bank of America Co. from $179.00 to $182.00. They now have a "buy" rating on the stock.
Ratings data for DGX provided by MarketBeat
Quest Diagnostics Incorporated (NYSE: DGX) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Ratings data for DGX provided by MarketBeat
Quest Diagnostics Incorporated (NYSE: DGX) was upgraded by analysts at Leerink Partners from a "market perform" rating to an "outperform" rating. They now have a $174.00 price target on the stock, up previously from $169.00.
Ratings data for DGX provided by MarketBeat
Quest Diagnostics Incorporated (NYSE: DGX) had its price target raised by analysts at Mizuho from $177.00 to $178.00. They now have an "outperform" rating on the stock.
Ratings data for DGX provided by MarketBeat
Quest Diagnostics Incorporated (NYSE: DGX) had its price target raised by analysts at Robert W. Baird from $190.00 to $191.00. They now have an "outperform" rating on the stock.
Ratings data for DGX provided by MarketBeat
Quest Diagnostics Incorporated (NYSE: DGX) is now covered by analysts at Redburn Atlantic. They set a "buy" rating and a $195.00 price target on the stock.
Ratings data for DGX provided by MarketBeat
Quest Diagnostics Incorporated (NYSE: DGX) had its price target raised by analysts at Mizuho from $178.00 to $189.00. They now have an "outperform" rating on the stock.
Ratings data for DGX provided by MarketBeat
Quest Diagnostics Incorporated (NYSE: DGX) had its price target raised by analysts at Robert W. Baird from $191.00 to $194.00. They now have an "outperform" rating on the stock.
Ratings data for DGX provided by MarketBeat
Quest Diagnostics Incorporated (NYSE: DGX) had its "outperform" rating re-affirmed by analysts at William Blair.
Ratings data for DGX provided by MarketBeat
Neueste Beiträge
BTIG_Research in Kirby Corp. diskutieren